This case report details a 54-year-old woman with metastatic non-small-cell lung cancer who experienced severe hairloss and exanthematous drug eruption, potentially linked to erlotinib hypersensitivity.
This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.
Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hairloss, while castor oil is recommended to strengthen hair roots and reduce shedding.
A 20-year-old male has been experiencing hairloss since age 15-16 and is using oral minoxidil, dutasteride, and ketoconazole shampoo, with previous use of oral finasteride and topical minoxidil. He has stabilized hairloss but seeks to rule out inflammatory or immune-related causes, considering a scalp biopsy, and is supplementing with vitamin D3, B12, and iron.
A user with PCOS experienced hairloss and found success using a triple dose of O.N.E Omega by Pure Encapsulations after discovering low Omega fatty acids. Biotin provided minimal improvement, but the Omega supplement significantly restored hair.
Federal funding cuts have delayed PP405 research, affecting hairloss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
A permanent hairloss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
Tried everything and still getting bald patches? Procapil may help calm the immune responseProcapil is a cosmetic ingredient complex; laboratory studies of its individual ingredients report anti-inflammatory effects, but no published clinical trial has tested it in alopecia areata or any other immune-related hair loss. Spreading bald patches should be assessed by a dermatologist.
What is tofacitinib, and why is it discussed in relation to autoimmune-relatedhairloss such as alopecia areata?Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
HMI-115: Frequently Asked Questions About HairLoss TreatmentHMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.